RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
Regen BioPharma Inc
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026
- Market cap
- $92.33K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0128 (−98.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Regen BioPharma Inc grew revenue 0.0% to $236.56K over the twelve months to Jun 30, 2026.
Revenue
$236.56K
0.0% vs. a year earlier
Operating income
-$803.86K
TTM Q3 2026
EPS, diluted
-$0.05
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $92.33K
- P/E ratio
- –
- Price to sales
- 0.39
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $236.56K
- Net income
- -$1.19M
- EPS, diluted
- -$0.05
- Book value per share
- -$0.01
- Diluted shares
- 616M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$236.56K0.0% YoY
Operating income
-$803.86K
Net income
-$1.19M
EPS, diluted
–
Reported periodTrailing twelve months